

Match Overview

1	CrossCheck 61 words Recent Results in Cancer Research, 2014.	3%
2	Internet 46 words crawled on 10-Mar-2016 www.spandidos-publications.com	2%
3	CrossCheck 44 words Claudine Isaacs. "Phase III study of sorafenib with anastrozole in patients with hormone receptor positive aron ...	2%
4	Internet 25 words crawled on 21-Aug-2014 www.hematologyandoncology.net	1%
5	Internet 24 words crawled on 21-Jun-2016 jco.ascopubs.org	1%
6	CrossCheck 21 words Dzēvīte, Agnese, Maruta Pranka, Tana Lace, Ritma Runģe, Edvīns Miklaševičs, and Janis Gardovskis. "Key Fa	1%
7	CrossCheck 18 words Fedele, Palma, Nicola Calvani, Antonella Marino, Laura Orlando, Paola Schiavone, Annamaria Quaranta, and Sa	1%
8	Internet 18 words crawled on 11-Apr-2016 onlinelibrary.wiley.com	1%
9	CrossCheck 17 words Baselga, J. J. G. M. Segalla, H. Roche, A. del Giglio, H. P. Inczowski, E. M. Ciruelos, S. C. Filho, P. Gomez, B. Van E	1%
	Publications 17 words	1.0%

17
Name of Journal: *World Journal of Clinical Oncology*

ESPS Manuscript NO: 26720

Manuscript Type: Minireviews

5
Sorafenib in breast cancer treatment: A systematic review and overview of clinical trials

Menelaos Zafarakas, Panayiota Papasozomenou, Christos Emmanouilides

Abstract

The aim of this study was to evaluate the current role of sorafenib, an oral multikinase inhibitor in the treatment of breast cancer. An extensive search of the literature until March 2016 was carried out in Medline and clinicaltrials.gov, by using the search terms "sorafenib" and "breast cancer". Papers found were checked for further relevant publications. Overall, 21 relevant studies were found, 18 in advanced breast cancer (16 in stage IV and two in stages III-IV) and three in early breast cancer. Among studies in advanced breast cancer, there were two trials with sorafenib as monotherapy, four trials of sorafenib in combination with taxanes, two in combination with capecitabine, one with gemcitabine and/or capecitabine, one with vinorelbine, one with bevacizumab, one with pemetrexed and one with ixabepilone, three trials of sorafenib in combination with endocrine therapy and two trials in women with brain metastases undergoing whole brain radiotherapy. In addition, there was one trial of sorafenib added to standard chemotherapy in the adjuvant setting, and two trials in the neoadjuvant setting. In general, sorafenib was well

tolerated in breast cancer patients, though its dosage had to be adjusted in some



全部

新闻

图片

视频

地图

更多 ▾

搜索工具

找到约 1,110,000 条结果 (用时 0.81 秒)

Google 学术: Sorafenib in breast cancer treatment: A systematic review and overview of clinical trials

... treatment of early-stage breast cancer: a systematic ... - Dahabreh - 被引用次数: 169

... : a systematic review and meta-analysis of clinical trials - Je - 被引用次数: 161

... overview of sorafenib, a multikinase inhibitor that ... - Wilhelm - 被引用次数: 808

Risk of gastrointestinal events with sorafenib, sunitinib and ... - NCBI

www.ncbi.nlm.nih.gov/pubmed/24127298 ▾ 翻译此页

作者: M Santoni - 2014 - 被引用次数: 21 - 相关文章

2013年11月18日 - Risk of gastrointestinal events with sorafenib, sunitinib and pazopanib in patients with solid tumors: a systematic review and meta-analysis of clinical trials. ... the incidence and relative risk (RR) in patients with cancer treated with these agents. ... Summary incidence, RR, and 95% CIs were calculated using ...

Targeted therapy in triple-negative metastatic breast cancer: a ... - NCBI

www.ncbi.nlm.nih.gov > NCBI > Literature > PubMed Central (PMC) ▾ 翻译此页

作者: O Clark - 2014 - 被引用次数: 13 - 相关文章

2014年1月6日 - The objective of this study was to perform a systematic review of the ... the National Cancer Institute Clinical Trials Service, and the Clinical Trials Register. The targeted therapies studied were Bev, sorafenib (Sor), cetuximab, summary for targeted therapy in triple-negative metastatic breast cancer.

Pruritus in Patients Treated with Targeted Cancer Therapies - NCBI

www.ncbi.nlm.nih.gov > NCBI > Literature > PubMed Central (PMC) ▾ 翻译此页

作者: CJ Ensslin - 2013 - 被引用次数: 19 - 相关文章

2013年8月24日 - A systematic review and meta-analysis of the literature was ... It is therefore clinically significant to determine the incidence of pruritus at this The summary RR for high-grade pruritus associated with targeted ... Phase II multicenter, uncontrolled trial of sorafenib in patients with

[全部](#)[新闻](#)[图片](#)[视频](#)[地图](#)[更多 ▾](#)[搜索工具](#)

找到约 1,270,000 条结果 (用时 1.37 秒)

Google 学术: Sorafenib in breast cancer treatment: A systematic review and overview of clinical trials

... : a systematic review and meta-analysis of clinical trials - Je - 被引用次数: 168

... overview of sorafenib, a multikinase inhibitor that ... - Wilhelm - 被引用次数: 839

Efficacy and safety of sorafenib in patients in the Asia- ... - Cheng - 被引用次数: 2625

小提示: 仅限搜索简体中文结果。您可以在设置中指定搜索语言

Risk of gastrointestinal events with sorafenib, sunitinib and pazopanib ...

www.ncbi.nlm.nih.gov/pubmed/24127298 ▾ 翻译此页

作者: M Santoni - 2014 - 被引用次数: 22 - 相关文章

2013年11月18日 - Risk of gastrointestinal events with sorafenib, sunitinib and pazopanib in patients with solid tumors: a systematic review and meta-analysis of clinical trials. the incidence and relative risk (RR) in patients with cancer treated with these agents. ... Summary incidence, RR, and 95% CIs were calculated using ...

Targeted therapy in triple-negative metastatic breast cancer: a ... - NCBI

www.ncbi.nlm.nih.gov > NCBI > Literature > PubMed Central (PMC) ▾ 翻译此页

作者: O Clark - 2014 - 被引用次数: 16 - 相关文章

2014年1月6日 - The objective of this study was to perform a systematic review of the ... the National Cancer Institute Clinical Trials Service, and the Clinical Trials Register. The targeted therapies studied were Bev, sorafenib (Sor), cetuximab, summary for targeted therapy in triple-negative metastatic breast cancer.

Treatment-related fatigue with sorafenib, sunitinib and pazopanib in ...

https://www.researchgate.net/.../259701100_Treatment-related_fatigue_with_sorafenib_...

Treatment-related fatigue with sorafenib, sunitinib and pazopanib in patients with advanced solid ...

[全部](#)[新闻](#)[图片](#)[视频](#)[地图](#)[更多 ▾](#)[搜索工具](#)

找到约 1,280,000 条结果 (用时 0.80 秒)

小提示： 仅限搜索[简体中文](#)结果。您可以在设置中指定搜索语言

Google 学术: Sorafenib in breast cancer treatment: A systematic review and overview of clinical trials

... : a systematic review and meta-analysis of clinical trials - Je - 被引用次数: 168

... overview of sorafenib, a multikinase inhibitor that ... - Wilhelm - 被引用次数: 841

Efficacy and safety of sorafenib in patients in the Asia- ... - Cheng - 被引用次数: 2635

Risk of gastrointestinal events with sorafenib, sunitinib and pazopanib ...

www.ncbi.nlm.nih.gov/pubmed/24127298 ▾ 翻译此页

作者: M Santoni - 2014 - 被引用次数: 22 - 相关文章

2013年11月18日 - Risk of gastrointestinal events with sorafenib, sunitinib and pazopanib in patients with solid tumors: a systematic review and meta-analysis of clinical trials. the incidence and relative risk (RR) in patients with cancer treated with these agents. ... Summary incidence, RR, and 95% CIs were calculated using ...

Targeted therapy in triple-negative metastatic breast cancer: a ... - NCBI

www.ncbi.nlm.nih.gov > NCBI > Literature > PubMed Central (PMC) ▾ 翻译此页

作者: O Clark - 2014 - 被引用次数: 16 - 相关文章

2014年1月6日 - The objective of this study was to perform a systematic review of the ... the National Cancer Institute Clinical Trials Service, and the Clinical Trials Register. The targeted therapies studied were Bev, sorafenib (Sor), cetuximab, ... summary for targeted therapy in triple-negative metastatic breast cancer.

Meta-Analysis of Randomized Controlled Trials for the Incidence and